Maria Branyas at 117: What Her Biology Reveals About Aging

Maria Branyas, who died in 2024 at the age of 117, became one of the most thoroughly studied humans in the history of longevity research. Scientists analysed her genome, proteins, metabolites, immune cells, gut microbiome and epigenetic markers, producing an unusually complete biological portrait of a person who had passed well beyond the typical limits of human lifespan. The findings complicate the simple idea that long life is just slow aging.

Instead, the data pointed to something closer to a paradox. Her cells showed clear evidence of advanced age: shortened telomeres, an immune system reshaped by decades of exposure, and molecular wear that would be expected after more than a century of living. At the same time, she carried markers usually associated with much younger and healthier people. Her epigenetic clocks, the chemical patterns on DNA used to estimate biological age, suggested she was roughly a decade younger than her chronological age.

Aging and protection, side by side

The combination researchers described was not a person who had escaped aging, but one who aged intensely while remaining shielded from its usual consequences. Inflammation, often called the common engine behind heart disease, dementia and frailty, was remarkably low. Her lipid profile and cholesterol metabolism resembled those of someone far younger. Markers of cellular stress that normally accumulate into disease appeared muted.

Her gut microbiome added another layer. It was dominated by bacteria associated with anti-inflammatory activity and gut barrier integrity, a profile more typical of a healthy younger adult than of a person in extreme old age. Whether this microbial composition helped protect her or simply reflected her overall state remains an open question, but the correlation was striking enough to draw attention.

Genetics also played a role. Analysis identified rare variants linked to immune regulation, cardiovascular health, cognitive resilience and efficient cellular repair. None of these alone explains 117 years of life, but together they suggest an inherited buffer against the diseases that end most lives decades earlier.

Why this case mattered scientifically

Most aging research is complicated by illness. Studies of very old people usually capture the effects of cancer, cardiovascular disease, diabetes or neurodegeneration layered on top of aging itself. Branyas developed none of these major conditions. Her mind remained sharp and her cardiovascular system stayed functional until close to the end.

That absence gave researchers something rare: a chance to observe aging as a process rather than as a collection of pathologies. It reinforced a growing argument in the field that lifespan and healthspan are governed by partly separate mechanisms, and that extending one does not automatically extend the other.

Her lifestyle, documented over many years, was unremarkable in the best sense. She ate a Mediterranean-style diet, consumed yogurt daily, avoided smoking and alcohol, maintained steady social contact, stayed mentally engaged and kept regular routines. Researchers were careful not to claim these habits caused her longevity, but they likely reinforced whatever biological advantages she already carried.

The limitation is obvious: this is a single individual. Findings from one person cannot be generalised into a blueprint for living past 110. Still, the study provides a set of testable hypotheses about inflammation control, lipid metabolism and microbiome composition that researchers can now pursue in larger populations.

What the Branyas case ultimately suggests is that extreme longevity may depend less on avoiding the biological damage of time and more on remaining resilient to it.